|
"huang c f"的相關文件
顯示項目 86-110 / 886 (共36頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2022-01-12T07:07:28Z |
GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution
|
HSIN-AN HOU; Lin Y.-C.; Kuo Y.-Y.; Chou W.-C.; Lin C.-C.; Liu C.-Y.; Chen C.-Y.; Lin L.-I.; Tseng M.-H.; Huang C.-F.; Chiang Y.-C.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Huang S.-Y.; Ko B.-S.; Hsu S.-C.; Wu S.-J.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-07T06:05:52Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; CHIH-YUAN LEE; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 國立成功大學 |
2022 |
Data science and reinforcement learning for price forecasting and raw material procurement in petrochemical industry
|
Lee, C.-Y.;Chou, B.-J.;Huang, C.-F. |
| 國立成功大學 |
2022 |
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan
|
Lo, C.-C.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Chang, T.S.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Chuang, W.-L.;Lin, H.-C.;Kao, J.-H.;Yu, M.-L.;investigators, TACR |
| 國立成功大學 |
2022 |
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
|
Huang, C.-F.;Tseng, K.-C.;Cheng, P.-N.;Hung, C.-H.;Lo, C.-C.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Chen, Chen C.-H.;Lee, P.-L.;Lin, C.-Y.;Kuo, H.-T.;Chen, Chen C.-T.;Yang, C.-C.;Huang, J.-F.;Tai, C.-M.;Hu, J.-T.;Lin, C.-L.;Su, W.-W.;Tsai, W.-L.;Huang, Y.-H.;Cheng, Cheng C.-Y.;Lin, C.-L.;Wang, C.-C.;Yang, S.-S.;Mo, L.-R.;Chen, G.-Y.;Chang, Chang C.-C.;Wang, S.-J.;Huang, C.-S.;Hsieh, T.-Y.;Lin, C.-W.;Lee, T.-H.;Chong, L.-W.;Huang, C.-W.;Chang, S.-N.;Tsai, M.-C.;Hsu, S.-J.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Lin, H.-C.;Lee, M.-H.;Tsai, P.-C.;Dai, C.-Y.;Chuang, W.-L.;Chen, Chen C.-Y.;Yu, M.-L. |
| 國立成功大學 |
2022 |
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
|
Chen, Y.-C.;Chang, T.-S.;Chen, Chen C.-H.;Cheng, P.-N.;Lo, C.-C.;Mo, L.-R.;Chen, Chen C.-T.;Huang, C.-F.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Chen, Chen C.-Y.;Tseng, K.-C.;Yu, M.-L.;investigators, on behalf of TACR |
| 國立成功大學 |
2022 |
Sofosbuvir/Velpatasvir for Hepatitis�C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng, P.-N.;Mo, L.-R.;Chen, Chen C.-T.;Chen, Chen C.-Y.;Huang, C.-F.;Kuo, H.-T.;Lo, C.-C.;Tseng, K.-C.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Chang, T.S.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Chou, K.-H.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Cheng, Cheng C.-Y.;Tsai, M.-C.;Liu, C.-J.;Dai, C.-Y.;Lin, H.-C.;Kao, J.-H.;Chuang, W.-L.;Yu, M.-L.;investigators, TACR |
| 臺大學術典藏 |
2021-12-22T03:53:44Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; JIANN-SHING JENG |
| 臺大學術典藏 |
2021-12-22T03:53:39Z |
Factors for recurrent stroke among Asian patients with non-valvular atrial fibrillation under non-vitamin K antagonist oral anticoagulant therapy
|
Lin S.-Y.; Tang S.-C.; Tsai L.-K.; Yeh S.-J.; Huang C.-F.; JIANN-SHING JENG |
| 臺大學術典藏 |
2021-12-22T03:53:33Z |
Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection
|
Lin S.-Y.; Peng Y.-F.; Huang C.-F.; Kuo C.-H.; Tang S.-C.; JIANN-SHING JENG |
| 臺大學術典藏 |
2021-12-22T03:53:31Z |
Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Ho L.-T.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; JIANN-SHING JENG |
| 臺大學術典藏 |
2021-12-22T03:53:29Z |
Impact of different renal function equations on direct oral anticoagulant concentrations
|
Lin S.-Y.; Kuo C.-H.; Huang T.-M.; Peng Y.-F.; Huang C.-F.; Tang S.-C.; JIANN-SHING JENG |
| 臺大學術典藏 |
2021-12-02T05:41:25Z |
Primary hypogammaglobulinemia presenting with prostate abscess and Fusobacterium mortiferum bacteremia in a 28-year-old man
|
Lu C.-H.; WANG-DA LIU; Huang C.-F.; Liao C.-H.; Lan T.-Y.; Kang C.-M.; Lin C.-C.; Yang Y.-H.; Hung C.-C. |
| 臺大學術典藏 |
2021-11-26T05:56:25Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; LI-KAI TSAI; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2021-11-26T05:56:20Z |
Factors for recurrent stroke among Asian patients with non-valvular atrial fibrillation under non-vitamin K antagonist oral anticoagulant therapy
|
Lin S.-Y.; Tang S.-C.; LI-KAI TSAI; Yeh S.-J.; Huang C.-F.; Jeng J.-S. |
| 臺大學術典藏 |
2021-10-18T06:51:39Z |
Ultrastructural changes of posterior lingual glands after hypoglossal denervation in hamsters
|
Cheng S.J.; Huang C.F.; Chen Y.C.; Lee J.J.; Chang H.H.; HSIN-MING CHEN; Chiang M.L.; Kuo M.Y.; Kok S.-H.; Tseng C.-Y. |
| 臺大學術典藏 |
2021-09-23T03:35:36Z |
Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection
|
Lin S.-Y.; Peng Y.-F.; Huang C.-F.; Kuo C.-H.; SUNG-CHUN TANG; Jeng J.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:54Z |
Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
|
Yu M.-L.; Liu C.-H.; Huang C.-F.; Tseng T.-C.; Huang J.-F.; Dai C.-Y.; Lin Z.-Y.; Chen S.-C.; Wang L.-Y.; Juo S.-H.H.; Chuang W.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:49Z |
Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype
|
Huang C.-F.; Yu M.-L.; JIA-HORNG KAO; Tseng T.-C.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Lin Z.-Y.; Chen S.-C.; Wang L.-Y.; Juo S.H.H.; Chuang W.-L.; Liu C.-H. |
| 臺大學術典藏 |
2021-09-04T06:11:44Z |
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Chen S.-I.; Lin J.-W.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:25Z |
Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:23Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:22Z |
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L. |
| 臺大學術典藏 |
2021-09-04T06:10:58Z |
Strategies to manage hepatitis C virus infection disease burden—Volume 4
|
Chen D.S.; Hamoudi W.; Mustapha B.; Layden J.; Nersesov A.; Reic T.; Garcia V.; Rios C.; Mateva L.; Njoya O.; Al-Busafi S.A.; Abdelmageed M.K.; Abdulla M.; Adda D.; Akin O.; Al Baqali A.; Al Dweik N.; Al Ejji K.; Al ghazzawi I.; Al Kaabi S.; Al Naamani K.; Al Qamish J.; Al Sadadi M.; Al Salman J.; AlBadri M.; Al-Romaihi H.E.; Ampofo W.; Antonov K.; Anyaike C.; Arome F.; Bane A.; Blach S.; Borodo M.M.; Brandon S.M.; Bright B.; Butt M.T.; Cardenas I.; Chan H.L.Y.; Chen C.J.; Chen P.J.; Chien R.N.; Chuang W.L.; Cuellar D.; Derbala M.; Elbardiny A.A.; Estes C.; Farag E.; Fung J.; Gamkrelidze I.; Genov J.; Ghandour Z.; Ghuloom M.; Gomez B.; Gunter J.; Habeeb J.; Hajelssedig O.; Himatt S.M.; Hrstic I.; Hu C.C.; Huang C.F.; Hui Y.T.; Jahis R.; Jelev D.; John A.K.; Kaliaskarova K.S.; Kamel Y.; JIA-HORNG KAO; Khamis J.; Khattabi H.; Khoudri I.; Konysbekova A.; Kotzev I.; Lai M.S.; Lao W.C.; Lee M.H.; Lesi O.; Li M.; Lo A.; Loo C.K.; Luk?i? B.; Maaroufi A.; Malu A.O.; Mitova R.; Mohamed R.; Morovi? M.; Murphy K.; Nde H.; Ngige E.; Njouom R.; Nonkovi? D.; Obekpa S.; Oguche S.; Okolo E.E.; Omede O.; Omuemu C.; Ondoa P.; Opare-Sem O.; Owusu-Ofori S.; Phillips R.O.; Prokopenko Y.N.; Razavi H.; Razavi-Shearer D.; Razavi-Shearer K.; Redae B.; Rinke de Wit T.; Robbins S.; Roberts L.R.; Sanad S.J.; Sharma M.; Simonova M.; Su T.H.; Sultan K.; Tan S.S.; Tchernev K.; Tsang O.T.Y.; Tsang S.; Tzeuton C.; Ugoeze S.; Uzochukwu B.; Vi R.; Vince A.; Wani H.U.; Wong V.W.S.; Workneh A.; Yacoub R.; Yesmembetov K.I.; Youbi M.; Yuen M.F.; Schmelzer J.D. |
| 臺大學術典藏 |
2021-09-04T06:10:57Z |
The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4
|
Chan H.L.Y.; Chen C.J.; Omede O.; Al Qamish J.; Al Naamani K.; Bane A.; Tan S.S.; Simonova M.; Cardenas I.; Derbala M.; Akin O.; Phillips R.O.; Abdelmageed M.K.; Abdulla M.; Adda D.; Al Baqali A.; Al Dweik N.; Al Ejji K.; Al ghazzawi I.; Al Kaabi S.; Al Sadadi M.; Al Salman J.; AlBadri M.; Al-Busafi S.A.; Al-Romaihi H.E.; Ampofo W.; Antonov K.; Anyaike C.; Arome F.; Blach S.; Borodo M.M.; Brandon S.M.; Bright B.; Butt M.T.; Chen D.S.; Chen P.J.; Chien R.N.; Chuang W.L.; Cuellar D.; Elbardiny A.A.; Estes C.; Farag E.; Fung J.; Gamkrelidze I.; Garcia V.; Genov J.; Ghandour Z.; Ghuloom M.; Gomez B.; Gunter J.; Habeeb J.; Hajelssedig O.; Hamoudi W.; Himatt S.M.; Hrstic I.; Hu C.C.; Huang C.F.; Hui Y.T.; Jahis R.; Jelev D.; John A.K.; Kaliaskarova K.S.; Kamel Y.; JIA-HORNG KAO; Khamis J.; Khattabi H.; Khoudri I.; Konysbekova A.; Kotzev I.; Lai M.S.; Lao W.C.; Layden J.; Lee M.H.; Lesi O.; Li M.; Lo A.; Loo C.K.; Luk?i? B.; Maaroufi A.; Malu A.O.; Mateva L.; Mitova R.; Mohamed R.; Morovi? M.; Murphy K.; Mustapha B.; Nersesov A.; Ngige E.; Njouom R.; Njoya O.; Nonkovi? D.; Obekpa S.; Oguche S.; Okolo E.E.; Omuemu C.; Ondoa P.; Opare-Sem O.; Owusu-Ofori S.; Prokopenko Y.N.; Razavi H.; Razavi-Shearer D.; Razavi-Shearer K.; Redae B.; Reic T.; Rinke de Wit T.; Rios C.; Robbins S.; Roberts L.R.; Sanad S.J.; Schmelzer J.D.; Sharma M.; Su T.H.; Sultan K.; Tchernev K.; Tsang O.T.Y.; Tsang S.; Tzeuton C.; Ugoeze S.; Uzochukwu B.; Vi R.; Vince A.; Wani H.U.; Wong V.W.S.; Workneh A.; Yacoub R.; Yesmembetov K.I.; Youbi M.; Yuen M.F.; Nde H. |
顯示項目 86-110 / 886 (共36頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
|
